|
Volumn 115, Issue 2, 2015, Pages 176-177
|
How active should active surveillance be?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
PROSTATE SPECIFIC ANTIGEN;
CANCER SPECIFIC SURVIVAL;
CANCER THERAPY;
CLINICAL PROTOCOL;
DISEASE SURVEILLANCE;
EDITORIAL;
GLEASON SCORE;
HUMAN;
PROSTATE BIOPSY;
PROSTATE CANCER;
TUMOR VOLUME;
BIOPSY;
BLOOD;
HEALTH SURVEY;
MALE;
PATHOLOGY;
PROSTATE;
PROSTATE TUMOR;
WATCHFUL WAITING;
BIOPSY;
CLINICAL PROTOCOLS;
HUMANS;
MALE;
POPULATION SURVEILLANCE;
PROSTATE;
PROSTATE-SPECIFIC ANTIGEN;
PROSTATIC NEOPLASMS;
WATCHFUL WAITING;
|
EID: 84921464214
PISSN: 14644096
EISSN: 1464410X
Source Type: Journal
DOI: 10.1111/bju.12859 Document Type: Editorial |
Times cited : (1)
|
References (6)
|